### Apremilast 75 mg extended release (Otezla XR 75 mg)

#### Notes:


- Quantity Limits: Yes
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- ^ Adequate trial is defined as the following:
  - o Phototherapy 8 weeks
  - o Methotrexate for psoriatic arthritis 3 months
  - o Topical steroids and colchicine for Behçet's disease- 3 months
  - o Psoriasis systemic medications 6 weeks

<u>Initiation (new start) criteria</u>: Non-formulary apremilast 75 mg extended release (Otezla XR 75 mg) will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- 1. Prescriber is a dermatologist and patient has a diagnosis of psoriasis
  - Patient is 6 years of age or older
  - Patient weighs 50 kg or more
  - Patient has failed an adequate trial<sup>^</sup> of phototherapy (unless documented by prescriber phototherapy not appropriate)
  - Patient has tried and failed an adequate trial<sup>^</sup> of, or patient has an allergy or intolerance<sup>\*</sup> to at least 1 of the following systemic medications (or contraindication to all):
    - Methotrexate
    - o Cyclosporine
    - Acitretin
  - Patient does not currently have an active prescription for a biologic DMARD or a Janus kinase inhibitor (oral or topical)
  - Patient has had a previous trial of apremilast immediate release (20 mg twice daily or 30 mg twice daily) with documented concerns about adherence to twice daily dosing
  - Patient is currently NOT taking any other medications dosed more than one time a day

kn org

Revised: 12/11/25 Effective: 02/19/26






### Apremilast 75 mg extended release (Otezla XR 75 mg)

- Prescriber is a dermatologist or rheumatologist and patient has a diagnosis of psoriatic arthritis
  - Patient is 6 years of age or older
  - · Patient weighs 50 kg or more
  - Patient has failed an adequate trial<sup>^</sup>, has an intolerance<sup>\*</sup> to, or has a contraindication to methotrexate (methotrexate not required if patient has dactylitis [inflammation of finger or toe] and/or enthesitis [inflammation of entheses])
  - Patient does not currently have an active prescription for a biologic DMARD or a Janus kinase inhibitor (oral or topical)
  - Patient has had a previous trial of apremilast immediate release (20 mg twice daily or 30 mg twice daily) with documented concerns about adherence to twice daily dosing
  - Patient is currently NOT taking any other medications dosed more than one time a day
- 3. Prescriber is a rheumatologist and patient has a diagnosis of oral ulcers associated with Behçet's disease
  - Patient is 18 years of age or older
  - Patient weighs 50 kg or more
  - Patient has failed an adequate trial^, has an intolerance\* to, or has a contraindication to the following:
    - o Topical steroids
    - Colchicine
  - Patient has had a previous trial of apremilast immediate release (20 mg twice daily or 30 mg twice daily) with documented concerns about adherence to twice daily dosing
  - Patient is currently NOT taking any other medications dosed more than one time a day

kp.org

Revised: 12/11/25 Effective: 02/19/26





#### Apremilast 75 mg extended release (Otezla XR 75 mg)

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Non-formulary apremilast 75
<u>mg extended release (Otezla XR 75 mg)</u> will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- 1. Prescriber is a dermatologist and patient has a diagnosis of psoriasis
  - Patient is 6 years of age or older
  - Patient weighs 50 kg or more
  - Patient does not currently have an active prescription for a biologic DMARD or a Janus kinase inhibitor (oral or topical)
  - Patient has had a previous trial of apremilast immediate release (20 mg twice daily or 30 mg twice daily) with documented concerns about adherence to twice daily dosing
  - Patient is currently NOT taking any other medications dosed more than one time a day
- 2. Prescriber is a dermatologist or rheumatologist and patient has a diagnosis of psoriatic arthritis
  - Patient is 6 years of age or older
  - Patient weighs 50 kg or more
  - Patient does not currently have an active prescription for a biologic DMARD or a Janus kinase inhibitor (oral or topical)
  - Patient has had a previous trial of apremilast immediate release (20 mg twice daily or 30 mg twice daily) with documented concerns about adherence to twice daily dosing
  - Patient is currently NOT taking any other medications dosed more than one time a day
- 3. Prescriber is a rheumatologist and patient has a diagnosis of oral ulcers associated with Behçet's disease
  - Patient is 18 years of age or older
  - Patient weighs 50 kg or more
  - Patient has had a previous trial of apremilast immediate release (20 mg twice daily or 30 mg twice daily) with documented concerns about adherence to twice daily dosing
  - Patient is currently NOT taking any other medications dosed more than one time a day

kp.org

Revised: 12/11/25 Effective: 02/19/26 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



Apremilast 75 mg extended release (Otezla XR 75 mg)

Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Non-formulary apremilast 75 mg extended release (Otezla XR 75 mg) will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- 1. Prescriber is a dermatologist and patient has a diagnosis of psoriasis
  - Patient has responded to apremilast as determined by prescriber
  - Patient does not currently have an active prescription for a biologic DMARD or a Janus kinase inhibitor (oral or topical)
  - Patient has had a previous trial of apremilast immediate release (20 mg twice daily or 30 mg twice daily) with documented concerns about adherence to twice daily dosing
  - Patient is currently NOT taking any other medications dosed more than one time a day
- 2. Prescriber is a dermatologist or rheumatologist and patient has a diagnosis of psoriatic arthritis
  - Patient has responded to apremilast as determined by prescriber
  - Patient does not currently have an active prescription for a biologic DMARD or a Janus kinase inhibitor (oral or topical)
  - Patient has had a previous trial of apremilast immediate release (20 mg twice daily or 30 mg twice daily) with documented concerns about adherence to twice daily dosing
  - Patient is currently NOT taking any other medications dosed more than one time a day
- 3. Prescriber is a rheumatologist and patient has a diagnosis of oral ulcers associated with Behçet's disease
  - Patient has responded to apremilast as determined by prescriber
  - Patient has had a previous trial of apremilast immediate release (20 mg twice daily or 30 mg twice daily) with documented concerns about adherence to twice daily dosing
  - Patient is currently NOT taking any other medications dosed more than one time a day

kp.org

Revised: 12/11/25 Effective: 02/19/26 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest

